Conformis, Inc. (CFMS): Price and Financial Metrics

Conformis, Inc. (CFMS): $0.35

0.00 (-1.07%)

POWR Rating

Component Grades














  • CFMS scores best on the Value dimension, with a Value rank ahead of 84.99% of US stocks.
  • The strongest trend for CFMS is in Growth, which has been heading down over the past 179 days.
  • CFMS ranks lowest in Momentum; there it ranks in the 19th percentile.

CFMS Stock Summary

  • CFMS has a higher market value than only 17.25% of US stocks; more precisely, its current market capitalization is $124,510,164.
  • In terms of volatility of its share price, CFMS is more volatile than 89.75% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CFMS comes in at -67.48% -- higher than that of only 6.33% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Conformis Inc are CTS, IRIX, KVHI, FOXF, and RWLK.
  • Visit CFMS's SEC page to see the company's official filings. To visit the company's web site, go to

CFMS Valuation Summary

  • CFMS's price/sales ratio is 3; this is 21.05% lower than that of the median Healthcare stock.
  • Over the past 75 months, CFMS's price/earnings ratio has gone up 38.5.
  • Over the past 75 months, CFMS's EV/EBIT ratio has gone up 30.

Below are key valuation metrics over time for CFMS.

Stock Date P/S P/B P/E EV/EBIT
CFMS 2021-08-31 3.0 2.5 22.6 14.3
CFMS 2021-08-30 2.9 2.4 21.8 13.6
CFMS 2021-08-27 2.7 2.2 20.3 12.3
CFMS 2021-08-26 2.8 2.3 20.7 12.7
CFMS 2021-08-25 2.6 2.1 19.2 11.4
CFMS 2021-08-24 2.5 2.0 18.6 10.8

CFMS Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at 90.83%.
  • Its 3 year net cashflow from operations growth rate is now at 53.49%.
  • Its 2 year cash and equivalents growth rate is now at -42.97%.
Over the past 34 months, CFMS's revenue has gone up $9,083,000.

The table below shows CFMS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 99.86 -8.399 -2.413
2021-09-30 101.133 -18.417 6.941
2021-06-30 103.001 -10.064 13.731
2021-03-31 66.121 -22.349 -26.446
2020-12-31 68.761 -18.31 -24.293
2020-09-30 71.953 -18.614 -23.104

CFMS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CFMS has a Quality Grade of B, ranking ahead of 76.62% of graded US stocks.
  • CFMS's asset turnover comes in at 0.884 -- ranking 27th of 186 Medical Equipment stocks.
  • CLPT, ANGO, and IVC are the stocks whose asset turnover ratios are most correlated with CFMS.

The table below shows CFMS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.884 0.672 0.319
2021-03-31 0.724 0.494 -0.538
2020-12-31 0.973 0.490 -0.465
2020-09-30 1.015 0.494 -0.415
2020-06-30 1.057 0.486 -0.449
2020-03-31 1.068 0.466 -0.503

CFMS Price Target

For more insight on analysts targets of CFMS, see our CFMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.33 Average Broker Recommendation 1.5 (Moderate Buy)

CFMS Stock Price Chart Interactive Chart >

Price chart for CFMS

CFMS Price/Volume Stats

Current price $0.35 52-week high $1.96
Prev. close $0.35 52-week low $0.27
Day low $0.34 Volume 150,600
Day high $0.36 Avg. volume 672,153
50-day MA $0.41 Dividend yield N/A
200-day MA $0.76 Market Cap 64.90M

Conformis, Inc. (CFMS) Company Bio

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. The company was founded in 2004 and is based in Bedford, Massachusetts.

CFMS Latest News Stream

Event/Time News Detail
Loading, please wait...

CFMS Latest Social Stream

Loading social stream, please wait...

View Full CFMS Social Stream

Latest CFMS News From Around the Web

Below are the latest news stories about Conformis Inc that investors may wish to consider to help them evaluate CFMS as an investment opportunity.

Conformis iTotal® CR Knee Replacement System Awarded “7A” Performance Rating from the U.K.’s Orthopaedic Data Evaluation Panel

Independently verified assessment of the performance of the fully personalized iTotal CR system over a 7-year period confirms that it meets the panel’s demanding standardsBILLERICA, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, today announced that the Orthopaedic Data Evaluation Panel in the United Kingdom (ODEP) awarded the Conformis iTotal® CR knee replacement system a

Yahoo | February 24, 2022

Conformis, Inc. to Participate in Upcoming Investor Conferences

BILLERICA, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in three upcoming investor conferences. March 8 – 42nd Annual Cowen Healthcare Conference The 42nd Annual Cowen Healthcare Conference will take place virtually March 7-9, 2022. Conformis management will pa

Yahoo | February 18, 2022

New Strong Sell Stocks for February 14th

CFMS, JD, and PZG have been added to the Zacks Rank #5 (Strong Sell) List on February 14, 2022

Yahoo | February 14, 2022

Investors in Conformis (NASDAQ:CFMS) have unfortunately lost 89% over the last five years

Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...

Yahoo | February 13, 2022

Smith+Nephew (SNN) to Acquire Orlando-Based Engage Surgical

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

Yahoo | January 26, 2022

Read More 'CFMS' Stories Here

CFMS Price Returns

1-mo -10.26%
3-mo -45.31%
6-mo -57.68%
1-year -66.35%
3-year -90.81%
5-year -91.78%
YTD -54.03%
2021 15.36%
2020 -56.00%
2019 316.67%
2018 -84.87%
2017 -70.62%

Continue Researching CFMS

Here are a few links from around the web to help you further your research on Conformis Inc's stock as an investment opportunity:

Conformis Inc (CFMS) Stock Price | Nasdaq
Conformis Inc (CFMS) Stock Quote, History and News - Yahoo Finance
Conformis Inc (CFMS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5562 seconds.